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Background
Cryo plus anti-CTLA-4 therapy induces antigen-specific
clonal T cell expansion, enhanced survival, and long-term
anti-tumor immunity in mice [1]. We recently demon-
strated that pre-operative cryo and/or anti-CTLA-4
therapy with Ipi is well tolerated and clinically feasible in
women with ESBC. Furthermore, cryo with or without Ipi
generates a polyclonal influx of novel T cell clones within
the tumor bed [2,3]. Here, we utilize T cell repertoire
analysis to explore the impact of cryo and/or Ipi on clonal
expansion within peripheral blood and TILs.
Methods
In a pilot study, women with ESBC were treated with cryo
7-10d before mastectomy (6 pts), single-dose Ipi (10 mg/
kg) 8-15d before mastectomy (6 pts), or cryo+Ipi (6 pts).
Peripheral blood mononuclear cells (PBMCs) and tumor
tissue were obtained pre-mastectomy (immediately
preceding cryo and/or 1-5d after Ipi), and at mastectomy.
T cell repertoire analysis was conducted on extracted
DNA using an Illumina® DNA deep sequencing platform
and ImmunoSEQ™ software. Clones comprising ≥0.01%
of sample DNA were analyzed, and results are reported
descriptively.
Results
Cryo with or without Ipi was associated with decreases in
absolute TIL count (median change: Ipi +6%, cryo -73%,
cryo+Ipi -16%). However, cryo+Ipi was associated with
the greatest expansion of TIL clones across the range of
102-104 amplicons (table 1), although no difference was
observed by group in PBMC clones. Across all samples, a
median of 523 TIL clones increased by ≥102 amplicons,
and a median of 4 TIL clones increased by ≥103 ampli-
cons. The Ipi/cryo group exceeded the median in 80%
(4/5) of cases. 21% of all TIL clones were detectable in
time-matched PBMC, whereas 16% of expanding (≥102)
TIL clones were detectable in time-matched PBMC.
Conclusion
Cryo plus Ipi expands more TIL clones than either strat-
egy alone. Therapy-associated clonal expansion may be
difficult to detect in PBMCs. These data highlight the
potential importance of TIL repertoire analysis for the
monitoring of pts treated with cryo and/or Ipi in the preo-
perative setting. In a follow-up randomized study, we will
evaluate whether TIL clonal expansion across the 102-104
range can be used to predict recurrence-free survival.
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Table 1 Therapy-associated T cell clonal expansion in TILs and PBMCs.
Median # TIL clones expanding by Median # PBMC clones expanding by
≥102 amplicons ≥103 amplicons ≥104 amplicons ≥102 amplicons ≥103 amplicons ≥104 amplicons
Cryo 199 2 0 697 1 0
Ipi 750 22 1 545 5 0
Cryo+Ipi 2010 85 1 830 1 0
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